Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eureka Therapeutics Undisclosed T-cell therapy (Multiple Myeloma)
- Development stage
- Preclinical
- Lead developer
- Eureka Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an engineered T-cell therapy currently in development for the treatment of multiple myeloma. Developed by Eureka Therapeutics in collaboration with Memorial Sloan Kettering Cancer Center and Juno Therapeutics (a subsidiary of Bristol Myers Squibb), the therapy utilizes Eureka's proprietary ARTEMIS and E-ALPHA platforms to target an undisclosed multiple myeloma antigen. This program originated from a 2016 licensing agreement that also included BCMA and GPRC5D-targeting therapies. The therapy employs fully-human binding domains to redirect T-cells against malignant plasma cells.
- Other names
- Undisclosed Target T Cells (Multiple Myeloma)
02
Targets
BCMA (B-cell maturation antigen)GPRC5D
Beyond the preview
Go deeper on Eureka Therapeutics Undisclosed T-cell therapy (Multiple Myeloma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eureka Therapeutics Undisclosed T-cell therapy (Multiple Myeloma).